TQH-2722
TQH-2722 is a humanized IgG4 anti-IL-4Rα monoclonal antibody. TQH-2722 targets the IL-4Rα receptor in humans, effectively disrupting the interaction between IL-4Rα and the downstream cytokines IL-4 and IL-13, thereby inhibiting inflammatory response. TQH-2722 can be used for the study of atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) [1].
Product Specifications
UNSPSC
12352203
Target
Interleukin Related
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
References & Citations
[1]Li X, et al. Safety, pharmacokinetics and population pharmacokinetic model of TQH2722, a novel IL-4Rα monoclonal antibody in healthy subjects: a phase I, first-in-human, single-dose and multiple-dose escalation study. J Pharm Sci. 2025 Jul;114 (7) :103773.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6182879-01 0.1 mL
IL27 (Interleukin 27, IL-27, IL-27A, IL27p28, IL30, MGC71873, p28) (HRP)
Ask
View Details 
MBS6182879-02 5x 0.1 mL
IL27 (Interleukin 27, IL-27, IL-27A, IL27p28, IL30, MGC71873, p28) (HRP)
Ask
View Details 
